HOWL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Werewolf Therapeutics Inc (HOWL) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks positive catalysts, has weak financial performance, and faces significant challenges including cash constraints and uncertain strategic partnerships. Analysts have downgraded the stock, and there are no strong trading signals or recent positive developments to justify an investment at this time.
The technical indicators suggest a bearish trend. The MACD is positive but contracting, RSI is neutral at 37.223, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 0.667, with key support at 0.618 and resistance at 0.717.
No significant positive catalysts identified. The MACD is slightly positive, but it is contracting.
Analysts have downgraded the stock, citing cash constraints and the need for strategic partnerships. Hedge funds are selling, with a significant increase in selling activity (755.50% over the last quarter). Financial performance is weak, with no revenue, declining net income, and negative EPS. No recent news or congress trading data provides support for the stock.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income drop to -$16.37 million (-1.82% YoY), EPS decline to -0.36 (-5.26% YoY), and gross margin dropped to 0 (-100% YoY).
Analysts have downgraded the stock. H.C. Wainwright lowered the price target from $10 to $4 but maintained a Buy rating. Wedbush downgraded the stock to Neutral from Outperform with a price target of $1 (down from $3), citing cash constraints and strategic challenges. Citizens also downgraded the stock to Market Perform, noting the need for partnerships or capital to advance clinical programs.
